Floatz logo

Firategrast

Multiple Sclerosis

GlaxoSmithKlineSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

183 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

Firategrast is also rated in:

relapsing-remitting multiple sclerosisDormant
CC
Indicative ·
44 / 100
View asset →
HealthyDormant
C
Indicative ·
39 / 100
View asset →
ObesityDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →